Diversity, equity and inclusion (DEI) continues to be a challenge for drug and medical device developers. While there has been some improvement in clinical trials, our guests note that unless there is a commercial or regulatory need, DEI is still an afterthought for many developers when designing clinical trials.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Ali Pashazadeh, CEO,Treehill Partners
Charlotte Jones-Burton, Board Member, bluebird bio; Founder & President, Women of Color in Pharma
Chia Chia Sun, Chief Commercial Officer, Fab Biopharma; CEO, Damiva
Phyllis Greenberger, Senior Vice President, Policy & Regulatory, Healthy Women
Todd Rudo, Chief Medical Officer, Clario
